TGA-approved coronavirus-killing labelling out in force
Monday, 06 April, 2020
A surface disinfectant produced by is reported to be the first product in Australia to carry the new Australian (TGA)-approved label claim against the SARS-CoV-2 (COVID-19) virus.
The TGA confirmed that 鈥淜ills Coronavirus, SARS-CoV-2 (COVID-19)鈥, which has been added to the product鈥檚 label.
The new label comes following new amendments to the TGA guidelines under , which allow listed disinfectants to make validated claims to kill the SARS-CoV-2 (COVID-19) virus on surfaces.
Viraclean is a hospital-grade disinfectant intended for use on a wide range of hospital surfaces that may be contaminated. The product can help the healthcare sector to protect hospital patients and staff from the risk of SARS-CoV-2 (COVID-19) virus cross-infection via inanimate high-touch objects and surfaces.
Chairman of Whiteley Corporation Dr Greg Whiteley said the new label claim will provide the Australian and New Zealand healthcare community with certainty around cleaning and disinfecting of healthcare surfaces and non-critical medical devices.
鈥淭his new label claim for Viraclean against the virus responsible for the current pandemic will add to certainty around the level of hygiene in hospitals, particularly in intensive care units, emergency departments and a range of other clinical, medical and dental applications,鈥 Dr Whiteley said.
The COVID-19 coronavirus has the capacity to survive on hard and relatively soft surfaces for a prolonged period of time, meaning that cleaning and disinfecting those surfaces is incredibly important to limit the spread of the virus.
Dr Whiteley explained that hospital surfaces around a patient who is infected with this virus will be contaminated by the patient shedding the virus.
鈥淭he testing against coronavirus in the case of this SARS-CoV-2 (COVID-19) relies on a number of surrogate viruses. This is important because using a surrogate protects the laboratory staff but allows a scientifically accurate representation of the disinfectant performance against all of the coronaviruses including SARS-CoV-2 (COVID-19) virus.
鈥淭his approach allows the TGA to manage the regulatory aspects of both the approval and also market performance to ensure public health standards are maintained.鈥
Victoria's Q3 median ED wait times the lowest on record
Victoria's quarter three performance data (January–March) has shown improvement across...
Irregularities in a clinician's cases prompt 15-month lookback
St Vincent's 黑料吃瓜群网 Sydney has detailed a 15-month lookback review — prompted by...
Two researchers receive $899,000 in cardiovascular funding
In heart-related news this Heart Week (5–11 May), two University of Newcastle researchers...